Evaluating space-time models for short-term cancer mortality risk predictions in small areas.

Biom J

Department of Statistics and Operations Research, Universidad Pública de Navarra, Campus de Arrosadía, 31006, Pamplona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Published: May 2014

Current cancer mortality data are available with a delay of roughly three years due to the administrative procedure necessary to create the registries. Therefore, health agencies rely on forecast cancer deaths. In this context, statistical procedures providing mortality/incidence risk predictions for different regions or health areas are very useful. These predictions are essential for defining priorities for cancer prevention and treatment. The main objective of this work is to evaluate the predictive performance of alternative spatio-temporal models for short-term cancer risk/counts prediction in small areas. All the models analyzed here are presented under a general-mixed model framework, providing a unified structure of presentation and facilitating the use of similar tools for computing the prediction mean squared error. Prostate cancer mortality data are used to illustrate the behavior of the different models in Spanish provinces.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bimj.201200259DOI Listing

Publication Analysis

Top Keywords

cancer mortality
12
models short-term
8
short-term cancer
8
risk predictions
8
small areas
8
mortality data
8
cancer
6
evaluating space-time
4
models
4
space-time models
4

Similar Publications

An approach to COVID‑19 and oncology: From impact, staging and management to vaccine outcomes in cancer patients: A systematic review and meta‑analysis.

Exp Ther Med

February 2025

Oncology Department, Princess Noorah Oncology Center, King Abdul Aziz Medical City, Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Centre, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Makkah-Jeddah Highway Road, Jeddah 22384, Saudi Arabia.

The COVID-19 pandemic has had a global impact, with >771 million confirmed cases and 6 million deaths reported by October 2023. Cancer patients, due to their immunosuppressed status, face an increased infection risk and higher COVID-19 complications. The present study aimed to assess clinical outcomes in COVID-19-infected cancer patients, focusing on mortality rates and other aspects, providing valuable insight for better protection and outcomes.

View Article and Find Full Text PDF

RNA nanotherapeutics for hepatocellular carcinoma treatment.

Theranostics

January 2025

Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness of current therapeutic options for advanced-stage disease. The efficacy of traditional treatments is often compromised by the intricate liver microenvironment and the inherent heterogeneity. RNA-based therapeutics offer a promising alternative, utilizing the innovative approach of targeting aberrant molecular pathways and modulating the tumor microenvironment.

View Article and Find Full Text PDF

Double outlet right ventricle (DORV) is a rare congenital heart defect where both the aorta and pulmonary artery originate from the right ventricle, often accompanied by additional cardiac anomalies to mitigate circulatory imbalance, though such compensations usually fail. We report a 15-month-old infant with recurrent respiratory infections and poor weight gain, referred for computed tomography angiography. Physical examination showed a small, non-syndromic infant with pallor, tachypnea, irritability, and finger clubbing.

View Article and Find Full Text PDF

Introduction: Peri-operative medicine is becoming increasingly relevant in the context of managing frail patients with cancer. This paper outlines how demographic shifts in populations are affecting cancer incidence and frailty rates, the relevance this holds to the management of cancer care, and the outcome measures that should be used to gauge best clinical practice to ensure patient-centred care.

Methods: A targeted literature review was conducted using the search terms 'surgical oncology', 'outcomes', 'frailty', 'quality of life' and 'end of life' from 10 to 17 June 2024.

View Article and Find Full Text PDF

Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20-25% of these cases acquire aggressive neuroendocrine (NE) features, ultimately leading to neuroendocrine prostate cancer (NEPC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!